Advertisement

Pathological Complete Response of HER2-Positive Breast Cancer to Trastuzumab and Chemotherapy Can Be Predicted by HSD17B4 Methylation

Identifying patients with HER2-positive breast cancer who would achieve pCR only by trastuzumab and chemotherapy may lead to surgery-free treatment.

 Oncotarget

click me